Author

Seth A. Ettenberg

Observed names: S A Ettenberg, S Ettenberg, S. Ettenberg, Seth A Ettenberg, Seth E. Ettenberg, Seth Ettenberg

Observed institutions: Genomics Institute of the Novartis Research Foundation, Novartis (Switzerland), National Institutes of Health, Pennsylvania State University, MorphoSys (Germany), Uniformed Services University of the Health Sciences, Pontificia Universidad Católica de Chile, Vanderbilt University, Walter Reed National Military Medical Center, LabCorp (United States), National Institute of Dental and Craniofacial Research, Integrated Oncology (United States), Novartis (United States), National Cancer Institute, National Cancer Institute, Center for Cancer Research, Vanderbilt-Ingram Cancer Center, Novartis Institutes for BioMedical Research, Penn State Milton S. Hershey Medical Center

OpenAlex ID: A5088475222

Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1

1999 · Gil Levkowitz, Hadassa Waterman, et al. · Molecular Cell · 1,001

Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

1999 · M M Keane, S A Ettenberg, et al. · PubMed · 552

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

2013 · Yannick Bulliard, Rose Jolicoeur, et al. · The Journal of Experimental Medicine · 447

PDF

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

2009 · Mariateresa Fulciniti, Pierfrancesco Tassone, et al. · Blood · 400

PDF

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

2001 · M Cuello, S A Ettenberg, et al. · PubMed · 372

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

2010 · Qing Sheng, Xinggang Liu, et al. · Cancer Cell · 234

PDF

Fas expression and function in normal and malignant breast cell lines.

1996 · M M Keane, S A Ettenberg, et al. · PubMed · 231

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

2004 · Antoinette R. Tan, Xiaowei Yang, et al. · Journal of Clinical Oncology · 176

Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex

2001 · Seth A. Ettenberg, Alessandra Magnifico, et al. · Journal of Biological Chemistry · 163

PDF

WW Domain HECT E3s Target Cbl RING Finger E3s for Proteasomal Degradation

2003 · Alessandra Magnifico, Seth Ettenberg, et al. · Journal of Biological Chemistry · 161

Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer Cells

2001 · Mauricio Cuello, Seth A. Ettenberg, et al. · Gynecologic Oncology · 152

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

2010 · Seth A. Ettenberg, Olga Charlat, et al. · Proceedings of the National Academy of Sciences · 150

LC−MS/MS Approach for Quantification of Therapeutic Proteins in Plasma Using a Protein Internal Standard and 2D-Solid-Phase Extraction Cleanup

2007 · Ziping Yang, Michael Hayes, et al. · Analytical Chemistry · 140

The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.

1996 · M M Keane, G A Lowrey, et al. · PubMed · 138

cbl-b inhibits epidermal growth factor receptor signaling

1999 · Seth A Ettenberg, Maccon M Keane, et al. · Oncogene · 128

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

2013 · Andrew P. Garner, Carl U. Bialucha, et al. · Cancer Research · 123

cbl-3: a new mammalian cbl family protein

1999 · Maccon M Keane, Seth A Ettenberg, et al. · Oncogene · 119

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

2014 · Heather A Huet, Joseph D Growney, et al. · mAbs · 109

PDF

Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines

2000 · Maccon M. Keane, Yaffa Rubinstein, et al. · Breast Cancer Research and Treatment · 106

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

2013 · Joan T. Garrett, Cammie R. Sutton, et al. · Cancer Research · 89

Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies

2016 · P Bernasconi-Elias, T Hu, et al. · Oncogene · 87

Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b

2004 · Gareth C Davies, Seth A Ettenberg, et al. · Oncogene · 87

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma

2015 · R H Prabhala, M Fulciniti, et al. · Leukemia · 77

Reversing LRP 5 -Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity

2013 · Ming-Kang Chang, Ina Kramer, et al. · Journal of Bone and Mineral Research · 76

PDF

Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors

2018 · Tinya Abrams, Anu Connor, et al. · Clinical Cancer Research · 61

Works count: 104

Citation count: 5,735

H-index: 29

I10-index: 35